Navigation Links
Heparin Antibodies May Put Patients At Risk

Patients developing antibodies to heparin, an anti-clotting drug, run the risk of either serious complications after undergoing a heart surgery, or death, according to a new research // . The Wake Forest University Baptist Medical Center’s professor of anesthesiology Thomas Slaughter said that the study aimed at finding out if an independent risk is posed by the development of heparin antibodies prior to the surgery.

Heparin is used in several procedures like heart catheterization or angioplasty, kidney dialysis, in addition to heart and vascular surgeries. Antibodies are developed in as many as 50% of the patients who are treated with heparin, the effect of which may even last for several months. The researchers are of the opinion that blood components are activated which cause inflammation and clotting in the case of subsequent treatment on patients who already carry heparin antibodies.

This will also lead to increased risks of strokes, heart rhythm problems, heart attacks, and other complications. The heparin antibody levels in the patients were studied by the researchers, before surgery, who came to the conclusion that the risk of hospitalization or death was twofold in the case of patients with the antibodies.

The Parsonnet risk score, a standardized risk scoring system was also used by the research scientists to ensure that the results of the study were not influenced by the baseline health status of the patients. The heparin antibodies were found in 13% of the patients who were to undergo surgery in the US.

Heparin can be easily be replaced by many other anti-clotting medications, but the Food and Drug Administration of the country will have to approve of them before they can be used. Patients may also postpone the surgery until the antibody levels in their bodies have subsided, which may at times take months together, and may not be practical if the patient concerned requires surgery immediately.


'"/>




Page: 1

Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Based Nanoscale Materials Developed For Dialysis Treatment
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Antibodies to fight HIV infection.
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. Scientists Develop Antibodies from Plant Seeds
8. Antibodies in Mother Affect Heart of Fetus
9. One in Three Heart Attack Patients Have No Chest Pains
10. Amphetamines Help Recovery of Stroke Patients
11. Painkillers Do Not Shorten Dying Patients Lives
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
Breaking Medicine Technology: